PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs BIIB |
|---|---|---|---|---|---|
| NVS | Novartis AG | 1.49 | 22.9 | 15.4% | — |
| BMY | Bristol-Myers Squibb Company | 2.73 | 14.2 | 5.2% | — |
| MRK | Merck & Co., Inc. | 5.13 | 108.8 | 21.2% | — |
| AMGN | Amgen Inc. | 8.88 | 26.1 | 2.9% | — |
| PFE | Pfizer Inc. | 22.97 | 35.4 | 1.5% | — |